Concenter BioPharma is currently raising funds for conducting this trial.
Concenter Biopharma granted approval for Phase 2a Clinical Trial at
Sheba Medical Center (Israel).
Zygosid-50 could be the first diabetes drug to restore near-normal cellular sensitivity to insulin, without side effects.
Concenter BioPharma is currently raising funds for conducting this trial. Concenter BioPharma's co-founder and CSO, Prof. Mottie (Mordechai) Chevion said: “the unique property of our drug candidate - Zygosid-50 is that it cancels out insulin resistance".
Comentários